Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
Current Obesity Reports · 03.01.2025 · 14 (1)
DOI: 10.1007/s13679-024-00598-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Obesity Reports, online erschienen am 03.01.2025. Verfasst von Lauren Moss und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA. Hauptthemen laut MEDLINE: Antidepressive Agents, Weight Gain, Obesity. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
PURPOSE OF REVIEW: To highlight recent research on antidepressant use and weight change and explore best clinical practices for reducing weight gain and obesity risk in individuals with depression. RECENT FINDINGS: Research on antidepressant use and weight gain suggests that genetic and biological factors including metabolizer phenotypes and inflammation can help to predict an individual's threshold for weight change among specific agents. For individuals with increased susceptibility to metabolic complications, medications including bupropion, fluoxetine, and newer agents (e.g., gepirone) have shown to be efficacious in improving depressive symptoms while concurrently reducing metabolic risks. Additional areas of focus following antidepressant related weight gain include switching to a weight neutral drug alternative, integrated behavioral interventions, and/or pharmacotherapy including GLP-1 receptor agonists (e.g., metformin, liraglutide). Individuals experiencing depression are at heightened risk of metabolic disorders and weight gain, which may be further exacerbated by antidepressant treatment. The increased support of weight neutral antidepressant agents in addition to innovative lifestyle interventions, breakthroughs in drug mechanisms, anti-obesity medications and overall familiarity with the side effects of each antidepressant class will help clinicians make appropriate decisions when treating patients with depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.
- Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.
- North Dakota State University, College of Health Professions, Fargo, ND, 58103, USA.
- Sanford Center for Biobehavioral Research, Fargo, ND, 58103, USA.
- Toronto Western Hospital Bariatric Surgery Program, Toronto, Canada.
- Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, M6J 1H4, Canada.
Zitieren
APA
Moss, L., Laudenslager, M., Steffen, K. J., Sockalingam, S., & Coughlin, J. W. (2025). Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications. Current Obesity Reports, 14(1). https://doi.org/10.1007/s13679-024-00598-5
Vancouver
Moss L, Laudenslager M, Steffen KJ, Sockalingam S, Coughlin JW. Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications. Current Obesity Reports. 2025;14(1). doi:10.1007/s13679-024-00598-5
BibTeX
@article{Moss2025,
author = {Moss, Lauren and Laudenslager, Marci and Steffen, Kristine J and Sockalingam, Sanjeev and Coughlin, Janelle W},
title = {Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications},
journal = {Current Obesity Reports},
year = {2025},
volume = {14},
number = {1},
doi = {10.1007/s13679-024-00598-5}
}
EUVIMED